3CAMM A J, KIRCHHOF P, LIP G Y, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) [J]. Eur Heart J, 2010, 31(19):2369- 2429.
4WANG Z, FERMINI B, NATTEL S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kvl. 5 cloned channel currents[J]. Circ Res, 1993, 73(6):1061-1076.
5FEDIDA D, WIBLE B, WANG Z, et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channelcurrent[J]. CircRes, 1993, 73(1):210-216.
6ELDSTROM J, WANG Z, XU H, et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD12B5) to Kvl. 5 channels [J]. Mol Pharmacol, 2007, 72(6): 1522-1534.
7CAMM A J, SAVEI.IEVA I. New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant[J]. J Interv Card Electrophysiol, 2008, 23(1): 7-14.
8EHRLICH J R, BII.ICZKI P, HOHNLOSER S H, et al. Atrial-selective approaches for the treatment of atrial fibrillation[J]. J AmCollCardiol, 2008, 51(8): 787-792.
9NACCARELLI G V, WOLBRETTE D L, SAMII S, et al. Vernakalant-a promising therapy for conversion of recent onset atrial fibrillation[J]. Expert Opin Investig Drugs 2008, 17(5): 805-810.
10European Medicines Agency. Assessment report for brinavess [EB/OL]. 2011. http://www, ema. europa, eu/docs/en_GB/ document_library/EPAR__ Public_ assess ment_report/human/ 001215/WC500097150. pdf EAeeessed 2011 Jan 171.
3Savelieva I, Camm J. Update on atrial fibrillation: part Ⅰ.Clin Cardiol, 2008,31 : 55-62.
4Savelieva I, Camm J. Update on atrial fibrillation: part Ⅱ. Clin Cardiol,2008,31 : 102-108.
5Wyse D G. Anticoagulation in atrial fibrillation: a contemporary viewpoint. Heart Rhythm, 2007,4(3 Suppl):S34-S39.
6DeSilvey D L. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial. Am J Geriatr Cardiol, 2006,15:326-327.
7Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF Ⅱ: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol, 2003,41:1445-1451.
8Testa L, Andreotti F, Biondi Zoccai G G, et al. Ximelagatran/melagatran against conventional anticoagulation: a metaanalysis based on 22,639 patients. Int J Cardiol, 2007,122: 117-124.
9Kaul S, Diamond G A, Weintraub W S. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol. 2005,46 : 1986-1995.
10Eriksson B I, Dahl O E, Rosencher N, et al. Dabigatran etexitate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, doubleblind, non-inferiority trial. Lancet, 2007,370 : 949-956.
